{"name":"Norgine","slug":"norgine","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":13,"colorKey":"oncology","drugs":[{"name":"COLOPEG","genericName":"COLOPEG","slug":"colopeg","indication":"Other","status":"marketed"},{"name":"CitraFleet","genericName":"CitraFleet","slug":"citrafleet","indication":"Bowel cleansing prior to colonoscopy","status":"marketed"},{"name":"Fleet","genericName":"Fleet","slug":"fleet","indication":"Other","status":"marketed"},{"name":"MOVICOL","genericName":"MOVICOL","slug":"movicol","indication":"Other","status":"marketed"},{"name":"MOVIPREP, 2-Day Split-Dosing","genericName":"MOVIPREP, 2-Day Split-Dosing","slug":"moviprep-2-day-split-dosing","indication":"Bowel cleansing prior to colonoscopy","status":"phase_3"},{"name":"Moviprep","genericName":"Moviprep","slug":"moviprep","indication":"Other","status":"marketed"},{"name":"NER1006","genericName":"NER1006","slug":"ner1006","indication":"Other","status":"marketed"},{"name":"NER1006, 2-Day Split-Dosing","genericName":"NER1006, 2-Day Split-Dosing","slug":"ner1006-2-day-split-dosing","indication":"Bowel preparation prior to colonoscopy","status":"phase_3"},{"name":"NER1006, Day Before-Only Dosing","genericName":"NER1006, Day Before-Only Dosing","slug":"ner1006-day-before-only-dosing","indication":"Bowel cleansing prior to colonoscopy","status":"phase_3"},{"name":"NER1006,1-Day Morning Split-Dosing","genericName":"NER1006,1-Day Morning Split-Dosing","slug":"ner1006-1-day-morning-split-dosing","indication":"Bowel cleansing prior to colonoscopy","status":"phase_3"},{"name":"PEG 3350 plus electrolytes","genericName":"PEG 3350 plus electrolytes","slug":"peg-3350-plus-electrolytes","indication":"Bowel preparation prior to colonoscopy or other gastrointestinal procedures","status":"phase_3"},{"name":"SP+MS, Day Before-Only Dosing","genericName":"SP+MS, Day Before-Only Dosing","slug":"sp-ms-day-before-only-dosing","indication":"Bowel cleansing prior to colonoscopy","status":"phase_3"},{"name":"Trisulfate solution","genericName":"Trisulfate solution","slug":"trisulfate-solution","indication":"Treatment of various conditions","status":"phase_3"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"NRL972","genericName":"NRL972","slug":"nrl972","indication":"Cystic fibrosis","status":"phase_3"}]}],"pipeline":[{"name":"COLOPEG","genericName":"COLOPEG","slug":"colopeg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CitraFleet","genericName":"CitraFleet","slug":"citrafleet","phase":"marketed","mechanism":"CitraFleet is an osmotic laxative bowel preparation that draws water into the colon to promote evacuation and cleanse the bowel.","indications":["Bowel cleansing prior to colonoscopy","Bowel cleansing prior to barium enema or other radiological examination of the colon"],"catalyst":""},{"name":"Fleet","genericName":"Fleet","slug":"fleet","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MOVICOL","genericName":"MOVICOL","slug":"movicol","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MOVIPREP, 2-Day Split-Dosing","genericName":"MOVIPREP, 2-Day Split-Dosing","slug":"moviprep-2-day-split-dosing","phase":"phase_3","mechanism":"MOVIPREP is an osmotic laxative bowel preparation that draws water into the colon to cleanse it before medical procedures.","indications":["Bowel cleansing prior to colonoscopy","Bowel cleansing prior to other gastrointestinal procedures"],"catalyst":""},{"name":"Moviprep","genericName":"Moviprep","slug":"moviprep","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"NER1006","genericName":"NER1006","slug":"ner1006","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"NER1006, 2-Day Split-Dosing","genericName":"NER1006, 2-Day Split-Dosing","slug":"ner1006-2-day-split-dosing","phase":"phase_3","mechanism":"NER1006 is a polyethylene glycol (PEG)-based bowel cleansing agent that osmotically draws fluid into the colon to evacuate intestinal contents.","indications":["Bowel preparation prior to colonoscopy"],"catalyst":""},{"name":"NER1006, Day Before-Only Dosing","genericName":"NER1006, Day Before-Only Dosing","slug":"ner1006-day-before-only-dosing","phase":"phase_3","mechanism":"NER1006 is a polyethylene glycol (PEG)-based bowel cleansing agent that osmotically draws fluid into the colon to evacuate intestinal contents.","indications":["Bowel cleansing prior to colonoscopy"],"catalyst":""},{"name":"NER1006,1-Day Morning Split-Dosing","genericName":"NER1006,1-Day Morning Split-Dosing","slug":"ner1006-1-day-morning-split-dosing","phase":"phase_3","mechanism":"NER1006 is a bowel cleansing agent that works as an osmotic laxative to purge the colon of fecal matter in preparation for colonoscopy.","indications":["Bowel cleansing prior to colonoscopy"],"catalyst":""},{"name":"NRL972","genericName":"NRL972","slug":"nrl972","phase":"phase_3","mechanism":"NRL972 is a selective inhibitor of neutrophil elastase that reduces protease-mediated tissue damage in inflammatory airway diseases.","indications":["Cystic fibrosis","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"PEG 3350 plus electrolytes","genericName":"PEG 3350 plus electrolytes","slug":"peg-3350-plus-electrolytes","phase":"phase_3","mechanism":"PEG 3350 plus electrolytes is an osmotic laxative that draws water into the bowel lumen to soften stool and promote bowel evacuation.","indications":["Bowel preparation prior to colonoscopy or other gastrointestinal procedures","Treatment of occasional constipation"],"catalyst":""},{"name":"SP+MS, Day Before-Only Dosing","genericName":"SP+MS, Day Before-Only Dosing","slug":"sp-ms-day-before-only-dosing","phase":"phase_3","mechanism":"SP+MS is a bowel preparation regimen combining sodium picosulfate and magnesium sulfate administered the day before a procedure to cleanse the colon.","indications":["Bowel cleansing prior to colonoscopy","Bowel cleansing prior to other colorectal procedures"],"catalyst":""},{"name":"Trisulfate solution","genericName":"Trisulfate solution","slug":"trisulfate-solution","phase":"phase_3","mechanism":"Trisulfate solution is a medication used to treat various conditions.","indications":["Treatment of various conditions"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOMERrZ0JPSlg3UjBIZWFKbk5oallCamxPN2dWQTBiTUwzanQtZ3lBUWNSeVAtRUdUckdYWW01QUxWQTNiaUtMRE0yNExtYmFiSlF6bTRQSlNyc1ZjdEZxdHFJMmxMeUJHaV8tbXZ4VWk1S1pyNkJQMjZCb3JHRE9wcDFfSm9BZDlXay04eHhoSnJ6R28wSEU2MmRNcmd0VnFfTWRCaUlybW5kdy1mWFRj?oc=5","date":"2026-03-05","type":"pipeline","source":"PharmTech.com","summary":"Norgine Announces $67M Strategic Investment to Boost UK Pharma Supply Resilience - PharmTech.com","headline":"Norgine Announces $67M Strategic Investment to Boost UK Pharma Supply Resilience","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPS2l5STJOOVBwY09wbjBuNTlmZjNwQ2tpbU5HU3FFVGNiY3Vka2dYbWhZNkY2ZWdVUnMzQk1IVE4wMWVrZXhndm1Jd0dvN3E1cnQ3RGhrdHNBQ3A5WEdDWVNsVlVIT3Juem5GcFkycFlsUmZDbjB2eHZsemQwVmZqZ1JKdXZiSE1vazRmVEhIYmRNU3laaVFDb01BTlhZZlpMMWtRTUlyM2dCNDVqeTF4Rm1jdzY3Vzh2bXhJ?oc=5","date":"2026-03-05","type":"pipeline","source":"GOV.UK","summary":"Medicine production expansion comes as Welsh Secretary announces new trade programme - GOV.UK","headline":"Medicine production expansion comes as Welsh Secretary announces new trade programme","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxQWWtnTmxQVGZCRUxFT1JIOHNoTDM5ZjN4RUU4ZUVteXg3VFQ2d1FLZzJqejlCdHJLcldyTFpJYkl2TlpfaHQ0Z25nZjM4SXhwRlJfeld3bnlndVdjTWhHNk9WODRoMDVFWE5oZ2NOeVlSMGNzRjVkZzUwT1hzMEJxN1hua2hZOFdNeHFuQ0dTSHhXUUlpaE5IaGY1MUhXQjJkdnJTdExRaXRzQjRWVVk4VU95bi0taUNLN3FjNGQ0cUtjdlNJZEM5UXlYMERyQmc?oc=5","date":"2025-12-22","type":"pipeline","source":"Contagion Live","summary":"Vir Grants Norgine Commercial Rights to Hepatitis Delta Therapy in Europe, Australia, and New Zealand - Contagion Live","headline":"Vir Grants Norgine Commercial Rights to Hepatitis Delta Therapy in Europe, Australia, and New Zealand","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQVlp1WDg1YkJURXBGd0Z4d2w0Q3h4bWs0dVBfZ2Jvd1VURWUyNURkOUFDUXZrU2pFb01taWFaNUoxR3NCc1k1a3hfcm1faTRkZ1NhMUE5SHNUVks0X1k3U0Fpd3FNM2NrMVhYN1lfVUNjMmhqUzlXeHpTSW1IZXBfc0dqQlZzRHdmakNiUTUyUHFCblpsMFBWWUpmOGVkVExNOWV2WFVWdXE?oc=5","date":"2025-12-17","type":"pipeline","source":"Fierce Biotech","summary":"Norgine gets in on Vir's hepatitis D program with €550M European licensing pact - Fierce Biotech","headline":"Norgine gets in on Vir's hepatitis D program with €550M European licensing pact","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQaUptdWdONUh6alFuOURaRURWQk5pVVJUWjFTd1BEOENrRDBNVWhTSl9WcTU1dnFBOGFVdk1FTm1pR1gwOUt3OHdxeG81ckdUb2R4a0djd1M2TkNkeXlYVEo5ZUVnZTJKSEJiZlI2MWZXVDZuV3J2WnM4OE1xbUdUR25HQkRKWlpZenRaZVQ0eHl6Y3dGU2ZSQnVqaHRVY04xcFBselJIdVc?oc=5","date":"2025-12-17","type":"pipeline","source":"Latham & Watkins LLP","summary":"Latham Advises Norgine on Exclusive Licensing Agreement With Vir Biotechnology - Latham & Watkins LLP","headline":"Latham Advises Norgine on Exclusive Licensing Agreement With Vir Biotechnology - Latham & Watkins LLP","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAJBVV95cUxOTVpCY203VDg4UzVjWUNPNGpLdnZLVjBQZlpmc0s3NkZPWGFiZWpCTE13WTU3bEdkalBvMDV0VVh0Ry1XUFBxbUJoOG5ZVnByR1g1d2ttaVFTQ3JnM2pSZ29uWmVIUnhpSlk4VW90RGk1aXpVNTQwVF9xM3drSmdGTE5fZTI1TjBINFhWUUtlU1pUcFNpRmlUMDU1aE9xVXJaWVJidHpCbEo1c1NiOEtTRmNYSFcyWUdRaUxrUzNuZGU1YnJvVWNTMXllZFdpbERWbDdUWFBKamVkM0otcm02SldraVlhZWM2V01TMExmSE9tOHNkY2FSMlVRTjV1TEdu?oc=5","date":"2025-12-17","type":"pipeline","source":"PR Newswire","summary":"Norgine enhances hepatology and specialty portfolio through exclusive in-licensing agreement with Vir Biotechnology - PR Newswire","headline":"Norgine enhances hepatology and specialty portfolio through exclusive in-licensing agreement with Vir Biotechnology","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-16","type":"deal","source":"Business Wire","summary":"Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECL","headline":"Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxOcGpWSFN1RWljWGo0YnZnekdjSDlPQngtSmhaNFhpaWtxa2xNel9DRFdOaFViQmE0VVRfTDNFMW1fbFNvc3plRDlRMjRuc21qeWZlSlBMbkxRMXNyd0preng1Uk03OHJUVHBFUEZnZWJNMnBPck1wTzlzQ1ZLYXlKTVBnWXREV2Jr?oc=5","date":"2025-08-14","type":"pipeline","source":"BioSpace","summary":"Norgine completes acquisition of Theravia - BioSpace","headline":"Norgine completes acquisition of Theravia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxPQzFIVjNYVUlGbExhQjR0SWN2RHNrNFd3blBnNzUzQnNYS3JJMnBsZkUwRXY4aklUdHFYMzFkNDIwVXl5c0FjQkJsRXZ3RDFyNEp0cTJta09UV3hrNmpqSmluQWZNeXo1Q1BMcEJpQkNMTDBJU0pCZVZRZ3NUOXJqTHVKSkJkemxTNmRRWjRvb19MZmR1Zk1heWNDS3IyYmg3TGd1ZGVYVkZ4YXNWWGFMMG1uMFpIbWFYckF6TjhNNnV5S0pZYlE?oc=5","date":"2025-04-17","type":"deal","source":"BioPharma APAC","summary":"Norgine to Acquire Theravia, Strengthening Its Rare Disease Portfolio Across Europe - BioPharma APAC","headline":"Norgine to Acquire Theravia, Strengthening Its Rare Disease Portfolio Across Europe","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxQeDNBekZVQ3VKckIyUjBPMHhVNXdvT1NsRWFpUGktNENUTURwR0xJbjM0TzNiXzdRQk9BRXVEbzBKYVpnVGY2WVlkQW9sckhSQzRkMHkxampsN1NDVVNQSkEwNTB4LVVTaktWNHBvaml1M1g4Mm9qV18wRUNPT3k1MU83Wk85SWs?oc=5","date":"2025-04-16","type":"deal","source":"Pharmaceutical Business review -","summary":"Norgine agrees to acquire pharma laboratory Theravia - Pharmaceutical Business review -","headline":"Norgine agrees to acquire pharma laboratory Theravia - Pharmaceutical Business review -","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxNYTF0UzZ2VTJSdVZ1VXV1cVY0WDVFN2NQTDZKS2IxSGxIb2oxVEd1TEtXUzR4RzdvbnNPUWRsQXViUHRTMGlHQ1BvMDQweVFhaTBiN0JKNk9CZDZQMUJDbEZhY1VGdHpxMy11cjEzbU9MenE2S3dYTFNETkxXMURkVElWcFZnOE0?oc=5","date":"2025-04-15","type":"deal","source":"pharmaphorum","summary":"Norgine on a growth charge again with Theravia takeover deal - pharmaphorum","headline":"Norgine on a growth charge again with Theravia takeover deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1sQnB4ei1sME5Qa3c2VHU1WTNDbWRFN0tWMDVqemx6WHRwWjVUOEtXMy0xVVhrNWI4NjVwaTRxaER5LVJYU1ZfdWZQT09ucmEwdlp3?oc=5","date":"2025-04-15","type":"pipeline","source":"FirstWord Pharma","summary":"Norgine snaps up Theravia to bolster rare disease portfolio - FirstWord Pharma","headline":"Norgine snaps up Theravia to bolster rare disease portfolio","sentiment":"neutral"}],"patents":[],"drugCount":14,"phaseCounts":{"marketed":6,"phase_3":8},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}